GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Aristo Bio-Tech and Lifescience Ltd (NSE:ARISTO) » Definitions » EBIT

Aristo Bio-Tech and Lifescience (NSE:ARISTO) EBIT : ₹99 Mil (TTM As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Aristo Bio-Tech and Lifescience EBIT?

Aristo Bio-Tech and Lifescience's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2024 was ₹71 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aristo Bio-Tech and Lifescience's annualized ROC % for the quarter that ended in Sep. 2024 was 17.55%. Aristo Bio-Tech and Lifescience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 28.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aristo Bio-Tech and Lifescience's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 9.69%.

Aristo Bio-Tech and Lifescience EBIT Historical Data

The historical data trend for Aristo Bio-Tech and Lifescience's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aristo Bio-Tech and Lifescience EBIT Chart

Aristo Bio-Tech and Lifescience Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
35.40 37.07 38.62 69.46 73.91

Aristo Bio-Tech and Lifescience Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EBIT Get a 7-Day Free Trial 43.73 25.73 46.02 27.90 70.89

Competitive Comparison of Aristo Bio-Tech and Lifescience's EBIT

For the Agricultural Inputs subindustry, Aristo Bio-Tech and Lifescience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aristo Bio-Tech and Lifescience's EV-to-EBIT Distribution in the Agriculture Industry

For the Agriculture industry and Basic Materials sector, Aristo Bio-Tech and Lifescience's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aristo Bio-Tech and Lifescience's EV-to-EBIT falls into.


;
;

Aristo Bio-Tech and Lifescience EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aristo Bio-Tech and Lifescience  (NSE:ARISTO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aristo Bio-Tech and Lifescience's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=137.278 * ( 1 - 24.96% )/( (567.316 + 606.576)/ 2 )
=103.0134112/586.946
=17.55 %

where

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1272.87 - 699.433 - ( 6.121 - max(0, 835.681 - 1050.256+6.121))
=567.316

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2232.833 - 1618.45 - ( 7.807 - max(0, 1762.52 - 1994.53+7.807))
=606.576

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Aristo Bio-Tech and Lifescience's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=141.784/( ( (217.998 + max(317.249, 0)) + (231.768 + max(229.39, 0)) )/ 2 )
=141.784/( ( 535.247 + 461.158 )/ 2 )
=141.784/498.2025
=28.46 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(574.73 + 401.866 + 67.539) - (699.433 + 0 + 27.453)
=317.249

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1422.74 + 447.127 + 3.6900000000001) - (1618.45 + 0 + 25.717)
=229.39

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aristo Bio-Tech and Lifescience's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=98.788/1019.071
=9.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aristo Bio-Tech and Lifescience EBIT Related Terms

Thank you for viewing the detailed overview of Aristo Bio-Tech and Lifescience's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Aristo Bio-Tech and Lifescience Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Aristo Bio-Tech and Lifescience Ltd (NSE:ARISTO) » Definitions » EBIT
Comparable Companies
BOM:524288 NSE:CLSL BOM:524408 BOM:524204 BOM:543643 BOM:530883 NSE:USASEEDS NSE:AGROPHOS NSE:AMBEY BOM:542123 CTVA TSX:NTR DSMD:IQCD SAU:2020 CF SZSE:000792 MOS OSL:YAR XTAE:ICL BOM:506395
Traded in Other Exchanges
N/A
Address
E-24, 25, 26, G.I.D.C, Manjusar, Taluka Savli, Vadodara, GJ, IND, 391775
Website
https://www.aristobiotech.com
Aristo Bio-Tech and Lifescience Ltd is an agrochemical company. It is mainly engaged in the manufacturing, formulation, supplying, packaging and job work services of various pesticides. The company exports products like Insecticides, Herbicides, Fungicides, Plant Growth Regulators and a wide variety of other Agrochemicals.

Aristo Bio-Tech and Lifescience Headlines

No Headlines